Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: Study

A study from Case Western Reserve University suggests that semaglutide, the main ingredient in Ozempic and Wegovy, may lower the risk of Alzheimer's disease in people with Type 2 diabetes. Reviewing records from over a million patients, researchers found that those on semaglutide had a reduced risk of Alzheimer's compared to other diabetes treatments.

The study found that semaglutide users were 70% less likely to develop Alzheimer's than those on insulin, and 40% less likely than those on other GLP-1 drugs. Women, in particular, showed a greater reduction in risk, potentially due to fewer heart-related health issues.

Despite these promising results, researchers caution against using semaglutide solely for Alzheimer's prevention. While it may help lower dementia risk factors, more studies are needed to confirm these findings and understand how the drug affects brain health.